Arthritis Featured Articles

1. Repurposing And Rescuing Pharmaceutical Drugs 4/26/2013

   Repurposing marketed drugs or rescuing compounds that failed in clinical trials offers entrepreneurs the potential to replenish pipelines with reduced risk and time.

2. Outsourcing Insights From The President Of A Virtual Drug Discovery Company 4/16/2013

   Carolyn Green, is the President and Director for Atreaon, Inc., a privately held biopharmaceutical company developing a novel engineered protein called Atsttrin, for the treatment of inflammatory diseases such as rheumatoid arthritis. Having recently completed a $20 million Series A financing to support the pre-clinical development of Atsttrin, Green took time out from her busy schedule to share some of her thoughts and insights regarding the outsourcing of clinical research.

3. Toxicometabolomics For Compound Attrition To Reduce Late Stage Failures Due To Safety 4/10/2013

   Many ’omics’ technologies have now become the primary way of discovering new biomarkers, and validation of these biomarkers is a relatively new and evolving concept. By Michael V. Milburn, John A. Ryals, and Lining Guo

4. Growing To Meet The Needs Of Big Pharma: Acquisitions Help BioClinica Increase Profits by 20% 3/26/2013

   Recent acquisitions have convinced Mark Weinstein, CEO of BioClinica, that his company is ready to work with the largest of pharmaceutical companies, be they CRO or drug sponsor. Bio-Imaging, which officially became BioClinica in 2009 following a major merger, is currently running over 400 imaging studies with over 200 clients. Weinstein notes a series of well-planned steps were required to get them to this position.

5. Clinical Trial Mgt. System Boosts Bottom Line 2/24/2012

   Since 1989, the Lynn Health Science Institute (LHSI) has been conducting comprehensive medical research. By Alec Fishburne and Malia McFatridge

6. Article: Trial Recruitment Without 'Trial And Error:' Validating Protocols And Identifying Investigators With Secondary Data Sources 7/25/2011
   For the past 10 years, pharmaceutical marketers have been using comprehensive, secondary databases and sophisticated analytics to reach the right physicians with the right educational messages. That same information and analytical approach can be used just as effectively to help clinical research organizations (CROs) select investigators and reach the right potential subjects for clinical studies. By Michel Denarie, IMS Health